TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4*
- Gareth J. Wayne‡,1,
- Su-Jun Deng§,1,
- Augustin Amour¶,1,
- Satty Borman¶,1,
- Rosalie Matico∥,1,
- H. Luke Carter§,1 and
- Gillian Murphy**,2
- ‡GlaxoSmithKline, New Frontiers Research Park, Harlow, Essex CM19 5AW, United Kingdom, §GlaxoSmithKline, Research Triangle Park, North Carolina 27709, ¶GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, United Kingdom, ∥GlaxoSmithKline, King of Prussia, Philadelphia, Pennsylvania 19406, and the **Department of Oncology, University of Cambridge and Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, United Kingdom
- ↵2 Supported by Cancer Research UK (C100). To whom correspondence should be addressed: Dept. of Oncology, University of Cambridge, Cancer Research UK Cambridge Inst., Robinson Way, Cambridge CB2 0RE, UK. Tel.: 44-1223-404-470; Fax: 44-1223-404-199; E-mail: gm290{at}cam.ac.uk.
Abstract
ADAMTS-4 (aggrecanase-1) is a glutamyl endopeptidase capable of generating catabolic fragments of aggrecan analogous to those released from articular cartilage during degenerative joint diseases such as osteoarthritis. Efficient aggrecanase activity requires the presence of sulfated glycosaminoglycans attached to the aggrecan core protein, implying the contribution of substrate recognition/binding site(s) to ADAMTS-4 activity. In this study, we developed a sensitive fluorescence resonance energy transfer peptide assay with a Km in the 10 μm range and utilized this assay to demonstrate that inhibition of full-length ADAMTS-4 by full-length TIMP-3 (a physiological inhibitor of metalloproteinases) is enhanced in the presence of aggrecan. Our data indicate that this interaction is mediated largely through the binding of glycosaminoglycans (specifically chondroitin 6-sulfate) of aggrecan to binding sites in the thrombospondin type 1 motif and spacer domains of ADAMTS-4 to form a complex with an improved binding affinity for TIMP-3 over free ADAMTS-4. The results of this study therefore indicate that the cartilage environment can modulate the function of enzyme-inhibitor systems and could have relevance for therapeutic approaches to aggrecanase modulation.
- Received November 20, 2006.
- Revision received April 19, 2007.
- The American Society for Biochemistry and Molecular Biology, Inc.











